Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06228560
Other study ID # P10-LP003-03
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date January 25, 2024
Est. completion date January 30, 2025

Study information

Verified date January 2024
Source Longbio Pharma
Contact Hongzhou Yang
Phone 021-58372390
Email yanghz@longbio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is a Phase II, multicenter, randomized, double-blind study to evaluatethe efficacy and safety of LP-003 administered subcutaneously as an add-on therapy for the treatment of adult patients aged 18-75 who have been diagnosed with refractory CSU and who remain symptomatic despitestandard-dose H1 antihistamine treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date January 30, 2025
Est. primary completion date January 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Aged 18 to 75 years at the screening period. 2. Presence of wheals with itching for = 6 weeks prior to randomization. At the screening visit, subjects had taken double or more than the approved dose, or a combination of two or more H1 antihistamines for the treatment of chronic spontaneous urticaria for at least 2 weeks. Within the 7 days preceding randomization, the Urticaria Activity Score 7 (UAS7) was =16 (range 0-42), Itch Severity Score 7 (ISS7) was =8 (range 0-21), at least one UAS (range 0-6) was =4 on any screening visit day, and there must be a current record of medication use. 3. Subjects must not miss more than one diary record (morning or night) within 7 days prior to randomization (day 1), and are willing and able to complete daily symptom electronic diary records during the study period; 4. Male participants and their partners or female participants must agree to take one or more non pharmacological contraceptive measures (such as complete abstinence, contraceptive ring, partner ligation, etc.) during the trial period and within 6 months after the end of the trial and have no plans for sperm or egg donation. 5. Agree to participate in this clinical trial and voluntarily sign an informed consent form. Exclusion Criteria: 1. The subject has a primary or sole trigger for chronic urticaria (chronic Induced urticaria), including artificial urticaria (symptomatic skin scratch disease), cold, heat, sun, pressure, delayed pressure, water, cholinergic, or contact urticaria; 2. Other medical conditions accompanied by symptoms of urticaria or angioedema including, but not limited to, urticarial vasculitis, pigmented urticaria, erythema multiforme, mastocytosis, hereditary urticaria, or drug-induced urticaria; 3. Any other dermatologic condition with chronic itching, such as atopic dermatitis, herpetic pemphigoid, herpetic dermatitis, senile itching, or psoriasis, which in the judgment of the Investigator may affect the evaluation of the study and the results of the study; 4. Subjects with clinically significant conditions such as (but not limited to) unstable ischemic heart disease, NYHA Class III/IV left ventricular failure, cardiac arrhythmias, uncontrolled hypertension, cerebrovascular disease, neurodegenerative, or other neurological disorders, uncontrolled hypothyroidism and hyperthyroidism and other autoimmune disorders, hypokalemia, hyper adrenergic state; past diagnosis of malignancy (other than basal cell carcinoma or squamous cell skin cancer); history of myocardial infarction within 12 months prior to screening; 5. Acute active infections requiring treatment at screening, including but not limited to, pulmonary infections, tuberculosis; 6. Positive hepatitis B surface antigen or hepatitis B core antibody (except for HBV-DNA testing below the lower limit of the research center's test) at screening; positive hepatitis C virus antibody, human immunodeficiency virus (HIV) antibody, and anti-syphilis helical antibody (TP-Ab) (except for those who are negative for RPR or TRUST); 7. Clinically significant cardiovascular, neurological, psychiatric, metabolic, hepatic, or other abnormalities identified during the Screening Period that may affect the interpretation of the study results and/or the safety of the subject; 8. Comorbid neurological or psychiatric disorders that prevent or prevent cooperation; patients with disabilities as defined by law (blindness, deafness, mute, mental retardation, psychiatric disorders, etc.); 9. Major surgery within 8 weeks prior to screening or surgery planned during the study period; 10. Evidence of historical or ongoing alcohol or substance abuse in the 6 months prior to screening; 11. Poor compliance, such as low medication adherence, inability to accurately complete a diary card, or use of prohibited medications; 12. Pregnant women, nursing mothers, or those with recent birth plans; 13. Patients who have participated in clinical trials of other drugs within the last 3 months; 14. Those who are considered by the investigator to be unfit to participate in the clinical trial.

Study Design


Intervention

Biological:
LP-003
Liquid in vial
Placebo
Liquid in vial
Omalizumab
Liquid in vial

Locations

Country Name City State
China Beijing Friendship Hospital, Capital Medical University Beijing Beijing
China Peking Union Medical College Hospital, Chinese Academy of Medical Sciences Beijing Beijing
China Peking University Third Hospital Beijing Beijing
China The First Affiliated Hospital of China Medical University Beijing Beijing
China The First Hospital of Peking University Beijing Beijing
China The Second XiangYa Hospital of Central South University Changsha Hunan
China The First Affiliated Hospital of PLA Army Medical University Chongqing Chongqing
China Fujian Medical University Union Hospital Fuzhou Fujian
China Dermatology Hospital of Southern Medical University Guangzhou Guangdong
China The Second Affiliated Hospital of Guangzhou Medical University Guangzhou Guangdong
China Hospital of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College Nanjing Jiangsu
China Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine Shanghai Shanghai
China Shanghai Skin Disease Hospital Shanghai Shanghai
China Shengjing Hospital of China Medical University Shenyang Liaoning
China Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan Hubei
China the Second Affiliated Hospital of Xi'an Jiaotong University Xi'an Shanxi

Sponsors (1)

Lead Sponsor Collaborator
Longbio Pharma

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The proportion of participants achieving complete absence of wheals and itching (UAS7 = 0) at week 12 Week 12
Secondary The incidence of adverse events during the study 40 weeks
Secondary The proportion of participants with no hives (HSS7 = 0) at week 4, 8, 12, 16, 20, 24, 32, and 40 Week 4, 8, 12, 16, 20, 24, 32, and 40
Secondary The proportion of participants achieving complete absence of wheals and itching (UAS7 = 0) at week 4, 8, 16, 20, 24, 32, and 40 Week 4, 8, 16, 20, 24, 32, and 40
Secondary The proportion of participants achieving complete absence of angioedema (AAS7 = 0) at week 4, 8, 12, 16, 20, 24, 32, and 40 Week 4, 8, 12, 16, 20, 24, 32, and 40
Secondary The proportion of participants with controlled disease activity (UAS7 = 6) at week 4, 8, 12, 16, 20, 24, 32, and 40 Week 4, 8, 12, 16, 20, 24, 32, and 40
Secondary Change From Baseline in UAS7, HSS7, ISS7, AAS7 at week 4, 8, 12, 16, 20, 24, 32, and 40 Baseline and week 4, 8, 12, 16, 20, 24, 32, and 40
Secondary Change From Baseline in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at week 4, 8, 12, 16, 20, 24, 32, and 40 Baseline and week 4, 8, 12, 16, 20, 24, 32, and 40
Secondary Blood concentrations of LP-003, free IgE, total IgE, anti-drug antibodies (ADA), and neutralizing antibodies (Nab) during the study 40 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06077773 - Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria Phase 2
Completed NCT04538794 - A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria Phase 1
Completed NCT01803763 - Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients Phase 2/Phase 3
Recruiting NCT05298215 - A Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous Urticaria Phase 2
Terminated NCT04612725 - A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO) Phase 2
Terminated NCT05528861 - A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria Phase 2
Completed NCT04109313 - An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU Phase 2
Completed NCT03580356 - A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines. Phase 3
Completed NCT03580369 - A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines Phase 3
Completed NCT05030311 - A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines Phase 3
Recruiting NCT06162728 - Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU) Phase 1/Phase 2
Completed NCT05107115 - Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine Phase 2
Recruiting NCT06042478 - A Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo and With Omalizumab as Active Control in CSU Adult Patients. Phase 3
Terminated NCT04159701 - A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria Phase 2
Completed NCT03749135 - Dupilumab in Chronic Spontaneous Urticaria Phase 2
Not yet recruiting NCT06396026 - A Study of Efficacy and Safety of TLL-018 in CSU Participants Phase 3
Completed NCT02649218 - A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients Phase 2
Active, not recruiting NCT05368285 - A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria Phase 2
Completed NCT05373355 - Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria. Phase 1
Not yet recruiting NCT06365879 - To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria Phase 3